Deans' stroke musings: Viz.Ai Artificial Intelligence Platform Demonstrates Improved Stroke Outcomes and Increased Trial Enrollment

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, March 21, 2021

Viz.Ai Artificial Intelligence Platform Demonstrates Improved Stroke Outcomes and Increased Trial Enrollment

Since all you are doing is 'care' and improved outcomes. I can see no use for this. You still don't know how fast tPA needs to be delivered to get 100% recovery. Until you know that you don't have a clue the goal you are shooting for. The goal is to deliver 100% recovery outcomes NOT 'improve outcomes'. Will you stop relying on your tyranny of low expectations to justify your failures?

Viz.Ai Artificial Intelligence Platform Demonstrates Improved Stroke Outcomes and Increased Trial Enrollment

March 19, 2021—Viz.Ai announced the presentation of data at International Stroke Conference 2021 that show the impact of the company’s artificial intelligence-powered platform to better coordinate care for acute ischemic and hemorrhagic stroke and improve clinical trial recruitment.

Ameer E. Hassan, DO, presented two studies that used Viz.Ai’s Viz LVO platform to improve care coordination for ischemic stroke patients requiring treatment across health systems and at a stand-alone center. According to the company, the data demonstrated reduced door-in door-out times at primary stroke centers (PSCs), improved door-in-to-puncture times at comprehensive stroke centers (CSCs), and improved reperfusion rates. Dr. Hassan is a neurologist at Valley Baptist Medical Center in Harlingen, Texas.

The first study compared the time between entering and leaving one of the 12 PSCs that are part of Valley Baptist before being transferred to the CSC for an emergent operation. Dr. Hassan reported significant average reduction in door-in door-out time (45%; 102.3 minutes) for patients whose care was coordinated through the Viz LVO application. In addition, there was an 11.4% improvement in modified Rankin Scale scores, which measure stroke outcomes.

The second study assessed the impact of Viz LVO on the time at the CSC between door-in to puncture time for nontransfer patients. Significant improvements in treatment time and revascularization were observed in patients treated using Viz LVO. Use of the software reduced the average procedure time by 86.7 minutes and offered a 10.8% improvement in the rate of good revascularization.

“Our two studies show that the incorporation of Viz LVO to coordinate care for ischemic stroke patients is associated with significant time savings across a hub and spoke model and also at comprehensive stroke centers.” commented Dr. Hassan in the company’s announcement. “Because we know that ‘time is brain,’ these improvements in the PSC and CSC settings could lead to significant advances in functional outcomes, reduced mortality and shorter hospital stays.”

In addition to these studies, Brian Jankowitz, MD, presented data that showed how artificial intelligence can automate the detection and triage of intracerebral hemorrhage (ICH) patients and subsequently increase enrollment velocity in clinical trials, noted Viz.Ai. Dr. Jankowitz is Director of the Cerebrovascular Program at Cooper University Health Care in Camden, New Jersey

According to Viz.ai, the companies clinical trial enrollment software, Viz RECRUIT, has led to faster patient detection and increased enrollment velocity in the AI ENRICH trial. AI ENRICH is a prospective trial that utilizes Viz RECRUIT to identify potentially eligible study subjects. The utilization of Viz.ai’s technology was associated with a 41% increase in screening rate and a 213% increase in enrollment rates.

“Viz ICH and Viz RECRUIT have increased enrollment in the AI ENRICH trial,” said Dr. Jankowitz. “Increasing enrollment velocity will enable a faster completion of the trial and ultimately help improve our understanding of this devastating condition.”